Please login to the form below

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

BMS and Celgene announce $74bn merger

setbacks in 2018 as it sought to grow beyond its myeloma blockbuster Revlimid.

Dragonfly signs Celgene as partner for NK cell platform

Celgene has been signing a string of research partnerships and licensing deals in the last couple of years to diversify its portfolio and reduce its reliance on Revlimid (lenalidomide), a drug

ASH18: CAR-T and drugs give new options for multiple myeloma

Ninlaro is already approved as a second-line therapy in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone, and Takeda is also trying to move its drug into the first-line

FDA green lights BMS’ multiple myeloma combo

That particular regimen also includes corticosteroid medication dexamethasone and Celgene’s blockbuster Revlimid, which generated around $8bn in sales last year.

FDA clears first-line use for J&J’s myeloma drug Darzalex

Later on, additional studies of Darzalex as an add-on to regimens based on Celgene’s Revlimid (lenalidomide) and in ASCT-eligible patients could further expand the opportunity in previously-untreated

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology